Gut bacteria joins fight against stubborn lung cancer
NCT ID NCT06448572
Summary
This study is testing whether adding a specific gut bacteria supplement (EXL01) to an immunotherapy drug (nivolumab) can help control advanced lung cancer that has stopped responding to standard treatments. It will involve about 21 patients who have already tried and progressed on immunotherapy and chemotherapy. The main goal is to see if this combination can stop the cancer from growing for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Lille
RECRUITINGLille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.